268 related articles for article (PubMed ID: 30888661)
1. Hutchinson-Gilford Progeria Syndrome: Challenges at Bench and Bedside.
Kreienkamp R; Gonzalo S
Subcell Biochem; 2019; 91():435-451. PubMed ID: 30888661
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
Kreienkamp R; Croke M; Neumann MA; Bedia-Diaz G; Graziano S; Dusso A; Dorsett D; Carlberg C; Gonzalo S
Oncotarget; 2016 May; 7(21):30018-31. PubMed ID: 27145372
[TBL] [Abstract][Full Text] [Related]
3. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.
Gonzalo S; Kreienkamp R; Askjaer P
Ageing Res Rev; 2017 Jan; 33():18-29. PubMed ID: 27374873
[TBL] [Abstract][Full Text] [Related]
4. Molecular insights into the premature aging disease progeria.
Vidak S; Foisner R
Histochem Cell Biol; 2016 Apr; 145(4):401-17. PubMed ID: 26847180
[TBL] [Abstract][Full Text] [Related]
5. Hutchinson-Gilford progeria syndrome through the lens of transcription.
Prokocimer M; Barkan R; Gruenbaum Y
Aging Cell; 2013 Aug; 12(4):533-43. PubMed ID: 23496208
[TBL] [Abstract][Full Text] [Related]
6. Towards delineating the chain of events that cause premature senescence in the accelerated aging syndrome Hutchinson-Gilford progeria (HGPS).
Dreesen O
Biochem Soc Trans; 2020 Jun; 48(3):981-991. PubMed ID: 32539085
[TBL] [Abstract][Full Text] [Related]
7. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
8. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
9. Towards a Drosophila model of Hutchinson-Gilford progeria syndrome.
Beard GS; Bridger JM; Kill IR; Tree DR
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1389-92. PubMed ID: 19021561
[TBL] [Abstract][Full Text] [Related]
10. Impairment of nuclear F-actin formation and its relevance to cellular phenotypes in Hutchinson-Gilford progeria syndrome.
Takahashi Y; Hiratsuka S; Machida N; Takahashi D; Matsushita J; Hozak P; Misteli T; Miyamoto K; Harata M
Nucleus; 2020 Dec; 11(1):250-263. PubMed ID: 32954953
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
12. Progerin reduces LAP2α-telomere association in Hutchinson-Gilford progeria.
Chojnowski A; Ong PF; Wong ES; Lim JS; Mutalif RA; Navasankari R; Dutta B; Yang H; Liow YY; Sze SK; Boudier T; Wright GD; Colman A; Burke B; Stewart CL; Dreesen O
Elife; 2015 Aug; 4():. PubMed ID: 26312502
[TBL] [Abstract][Full Text] [Related]
13. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
Gabriel D; Roedl D; Gordon LB; Djabali K
Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
[TBL] [Abstract][Full Text] [Related]
14. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome.
Liu GH; Barkho BZ; Ruiz S; Diep D; Qu J; Yang SL; Panopoulos AD; Suzuki K; Kurian L; Walsh C; Thompson J; Boue S; Fung HL; Sancho-Martinez I; Zhang K; Yates J; Izpisua Belmonte JC
Nature; 2011 Apr; 472(7342):221-5. PubMed ID: 21346760
[TBL] [Abstract][Full Text] [Related]
15. Nuclear lamins and progerin are dispensable for antioxidant Nrf2 response to arsenic and cadmium.
Hashimoto K; Majumdar R; Tsuji Y
Cell Signal; 2017 May; 33():69-78. PubMed ID: 28229933
[TBL] [Abstract][Full Text] [Related]
16. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
17. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
18. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
19. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
20. Genomic instability and innate immune responses to self-DNA in progeria.
Gonzalo S; Coll-Bonfill N
Geroscience; 2019 Jun; 41(3):255-266. PubMed ID: 31280482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
